Objective: Bloodstream infection (BSI) is a well-recognized problem and it affects 10-50% of solid organ transplant recipients. The purpose of this study was to assess the incidence and prognosis of BSI in heart transplant recipients at our hospital. Methods: The study is a retrospective chart review. Results: We diagnosed 101 episodes of BSI in 73 out of 306 heart transplant patients (24%) during the 12-year study period. BSI occurred at a median of 191 days (range 1-3376) after transplant and 50% occurred within 6 months after transplant. Most BSI episodes were nosocomial (73%), especially those occurring within the first month (94%). As far as pathogen was concerned, Gram-negative bacteria predominated (57%), followed by Gram-positive bacteria (34%), fungus (5%), anaerobics (2%), and cryptococcus (2%). Overall 30-day mortality rate was 30%. Death occurred in 36% (13/36) of the patients with early-onset BSI, 14% (2/14) of the patients with BSI in months 2-6, and 29% (15/ 51) of the patients with late-onset BSI. Mortality rate was over 50% in those patients with Pseudomonal infection, fungal infection, cryptococcal infection of central nervous system, lung infection, and severe sepsis. Compared to Western series, there was a high incidence of infections caused by Enterobacter species and Acinetobacter baumannii. Conclusions: There was a high incidence of BSI after heart transplantation in Taiwan, especially infections caused by Enterobacter species and A. baumannii. Mortality was high in patients with infection caused by Pseudomonas, Candida, and Cryptococcus and in patients with severe sepsis. #
Introduction
Infection is a common cause of morbidity and mortality in patients with solid organ transplantation [1] [2] [3] [4] . The sites of infection include blood, respiratory tract, urinary tract, and surgical wounds. Bloodstream infection (BSI) is a wellrecognized problem and it affects 28-30% of liver transplant recipients, 5-11% of kidney recipients, and 25% of lung recipients, but information is limited in heart transplant recipients [5] . The incidence and type of BSI are influenced by several factors including type of organ transplant; the type, duration, and intensity of immunosuppressive drugs; the prophylactic antimicrobial strategies after transplantation; and, most particularly, geographic differences in the exposure to community and hospital-acquired pathogens [1, 5, 6] . We have reported that certain types of infectious complications after heart transplantation were different in Taiwan [7, 8] . The purpose of this study was to assess the incidence of BSI in heart transplant recipients at our hospital and to evaluate the difference between Taiwan and Western series.
Patients and methods

Patients
A total of 316 consecutive patients underwent heart transplantation from July 1987 through July 2008 at National Taiwan University Hospital. There were 262 males and 54 females with the mean age of 44.8 AE 16.3 years (range, 6 months to 71 years) at transplantation. Heart transplantation was indicated by the following heart diseases: dilated cardiomyopathy in 172 patients (54%), ischemic cardiomyopathy in 91 patients (29%), and other cardiac diseases in 53 patients (17%). All transplant recipients who survived and were hospitalized with blood cultures positive for pathogens between October 1995 and October 2007 were included in www.elsevier.com/locate/ejcts European Journal of Cardio-thoracic Surgery 40 (2011) [1362] [1363] [1364] [1365] [1366] [1367] this study. Culturing of specimens was performed at a clinical microbiology laboratory, and bacteria were identified using conventional culture-based methods and the VITEK and/or API systems [9] .
Pretransplantation clinical and demographic information on the transplant recipients and donors, type of immunosuppression, type of perioperative infectious prophylaxis, follow-up clinical information, and incidence and type of BSI were collected and recorded. The BSI was listed according to type of organism (bacterium, virus, fungus, or parasite), source of infection, time of onset of infection after transplant, and clinical outcome.
Immunosuppression
All patients received triple-drug immunosuppressive therapy according to our heart transplantation protocol described earlier [8] . Since 1995, we started to use rabbit antithymocyte globulins for induction therapy. Azathioprine (4 mg kg À1 ) was given 1 h before the operation. Solumedrol (1000 mg) was infused during release of the aortic crossclamp.
Rabbit antithymocyte globulin (1.5-2.5 mg kg À1 day À1 ) was given after transplantation for 5 days. Cyclosporine was started orally within 5 days after transplantation or after the recovery of renal function. Cyclosporine dose was adjusted according to renal function and serum cyclosporine level, which was maintained at the trough level of 300-500 ng ml À1 during the first 3 months after transplantation and 200-300 ng ml À1 1 year after transplantation.
Azathioprine was given at 1-2 mg kg À1 day À1 after transplantation, with the dose adjusted to maintain a white blood cell count of 4000-6000 mm À3 . Prednisone (0.5 mg kg À1 day À1 ) was started on the second postoperative day and tapered to 0.2 mg kg À1 day À1 by the first month after transplantation. Tacrolimus (FK-506) and mycophenolate mofetil (Cellcept) were used for recurrent rejection or severe adverse reactions to cyclosporine and azathioprine. Since 2004, we started to use mycophenolate mofetil for primary immunosuppression instead of azathioprine. To prevent nephrotoxicity, cyclosporine dose was decreased to maintain serum trough level of 250-350 ng ml À1 during the first 3 months after transplantation and 150-250 ng ml À1 1 year after transplantation. All patients were followed up monthly at a special cardiac transplantation clinic. Standard chest roentgenogram, blood tests, electrocardiogram, and physical examinations were routinely performed at regular intervals. The mean follow-up duration was 46.7 AE 38.4 months. None of them was lost to follow-up.
Prophylactic regimen
Perioperative prophylactic antibiotics included 1 g of cefazolin given intravenously to recipients every 8 h until removal of endotracheal tube and drain tubes. In an attempt to prevent oropharyngeal candidiasis, mycostatin suspension (5 cc, swish and swallow) was given orally 4 times a day for 1 month after transplantation. Acyclovir 200 mg every 6 h was used for prophylaxis against herpes simplex virus and varicella zoster virus for 1 month after transplantation. No prophylactic agents were used for prevention of Pneumocystis jiroveci infection and Mycobacterium tuberculosis infection. Trimethoprim-sulfamethoxazole prophylaxis (one double-strength tablet twice a day) was given for 6 months after transplantation in those patients who were seropositive for Toxoplasma gondii or who received donors seropositive for T. gondii. If the recipients had positive cytomegalovirus antibody preoperatively, no specific prophylaxis was given. Intravenous ganciclovir was administered after transplantation for 1 month only in those cases where the donor was positive and the recipient was negative for cytomegalovirus antibodies. These patients also received intravenous human cytomegalovirus immunoglobulin for 6 weeks [10] .
Definition
We considered BSI as significant when one or more microorganisms were isolated in one or several blood cultures. Specimens for culture were obtained when clinically indicated, and no surveillance was routinely performed. In cases involving microorganisms of doubtful significance (e.g., Bacillus species, nonhemolytic Streptococcus species, and coagulase-negative Staphylococcus species), clinically relevant episodes were defined as those in which there was evidence of clinical infection with no other explanation and in which the microorganisms were isolated from two or more different blood cultures. BSI was considered community acquired if the first positive blood culture specimen was taken in outpatients or within the first 48 h after admission. After this period (or before, if it was clearly related to an invasive procedure carried out in the hospital), the infection was considered nosocomial. The source of BSI was considered documented if there were focal signs or symptoms of infection and/or the same microorganism was isolated from blood and the infected site. In the absence of a recognized source, BSI was classified as primary.
Systemic inflammatory response syndrome (SIRS) is defined as an inflammatory response to a variety of clinical insults manifested by two or more of temperature >38 8C or <36 8C, heart rate >90 min À1 , respiratory rate >20 min À1 , or PaCO 2 <32 mmHg, white cell count >12k or <4k or >10% immature forms. Sepsis is defined as infection plus systemic manifestations of infection (SIRS). Severe sepsis is defined as sepsis plus sepsis-induced organ dysfunction or tissue hypoperfusion. Septic shock is defined as sepsis-induced hypotension persisting despite adequate fluid resuscitation. Acute Physiology And Chronic Health Evaluation (APACHE) scores were not available because not every patient underwent detailed blood biochemistry and blood gas analyses at the time of BSI. Mortality was defined by deaths within 1 month of positive blood culture.
Empirical antimicrobial therapy for patients with clinical suspicion of BSI was intravenous ampicillin/sulbactam for patients with uncomplicated infection and intravenous vancomycin plus third-or fourth-generation cephalosporin for patients with severe sepsis. Antibiotic was modified based on the culture result and the sensitivity test.
Statistical analysis
The results are expressed as median with a range or as frequencies for the categorical variables. The survival curve was plotted by the Kaplan-Meier method. Statistical differences between groups were calculated using Fisher exact test. Differences were considered significant at p < 0.05.
Results
Causes of death
Among 316 heart transplant patients, 145 patients died after heart transplantation. The 1-year, 5-year, and 10-year survival rates by Kaplan-Meier method were 80.7 AE 2.2%, 60.6 AE 3.0%, and 42.1 AE 3.6%, respectively. The causes of death were categorized by time after transplant. Within the first 30 days after transplant, infection accounted for 60% of the deaths in 25 patients, followed by surgical bleeding (20%) and acute rejection (12%). From 31 days to 1 year after transplant, infection accounted for 40% of the deaths in 35 patients, followed by acute rejection (26%), sudden death (14%), and non-specific acute allograft failure (9%). From 1 year to 5 years after transplant, sudden death accounted for 24% of the deaths in 51 patients, followed by infection (22%), cardiac allograft vasculopathy (22%), non-specific acute allograft failure (16%), acute rejection (8%), and malignancy (4%). After 5 years, cardiac allograft vasculopathy accounted for 30% of the deaths, followed by sudden death (27%), infection (13%), malignancy (13%), and non-specific acute allograft failure (7%). Infection was the leading cause of early death within 1 year after transplant and its significance decreased gradually with time after transplant.
BSI
After exclusion of 10 patients who died before October 1995, the remaining 306 patients were evaluated during the study period. As shown in Table 1 , we diagnosed 101 episodes of BSI in 73 out of 306 patients (24%). BSI occurred at the median of 191 days (range 1-3376) after transplant and half of them occurred within the first 6 months after transplant. Most episodes were nosocomially acquired (73%), especially those occurring within the first month after transplant (94%).
Pathogen
As far as pathogen was concerned (Table 1) , Gramnegative bacteria predominated (57%), followed by Grampositive bacteria (34%), Candida (5%), anaerobics (2%), and cryptococcus (2%). Seventeen percent episodes were polymicrobial. Gram-negatives accounted for 54% of infections in the first month, 50% during months 2-6, and 72% of infections occurring afterwards. Escherichia coli, Pseudomonas species, Klebsiella species, Enterobacter cloacae, and Acinetobacter baumannii were the Gram-negative bacilli seen most often in our recipients. Staphylococcus aureus and Staphylococcus epidermidis were the predominant Gram-positive organisms. Anaerobic Propionibacterium acnes was present in two patients. Regarding the portal of entry, primary bacteremia (61%) and catheter-related BSI (21%) were the most frequent sources.
Time of onset
As many as 33% (36/101) of the BSI occurred within 1 month after transplant and were considered to be early onset. The predominant microorganisms seen in these early BSI were E. cloaca, A. baumannii, Pseudomonas species, Klebsiella species, and S. aureus. A total of 14% (14/101) of the BSI occurred between 2 and 6 months after transplant. The predominant microorganisms seen in months 2-6 were Gram-positive cocci (S. aureus and S. epidermidis). Fifty percent (51/101) of the BSI occurred over 6 months after transplant and were considered to be late onset. The predominant microorganisms seen in these late bacteremias were E. coli, S. aureus, S. epidermidis, and Klebsiella species.
Mortality
The 30-day mortality rate after BSI for all patients was 30%. Death occurred in 36% (13/36) of the patients with early-onset BSI, 14% (2/14) of the patients with BSI in months 2-6, 29% (15/51) of the patients with late-onset BSI. The mortality rate was 29% in patients with Gram-negative bacteremia, 27% in patients with Gram-positive bacteremia, 67% in patients with fungemia, and 0% in patients with anaerobic bacteremia. No significant change in mortality was observed with time after transplant. However, the mortality rate was 50% in patients with Pseudomonal infection, candidal infection, cryptococcal infection of central nervous system, lung infection, and severe sepsis (Table 1) . Patients with severe sepsis had a significantly higher mortality than patients without sepsis ( p < 0.001 by Fisher's exact test).
Comparison with Western series
The comparison of patient characteristics and incidence of BSI after transplantation between our series and Western series [1, 5, 11, 12] is listed in Table 2 . In our patients, there was a significantly high incidence of infections caused by Enterobacter species and A. baumannii ( p = 0.002 and p = 0.026, respectively, between Hsu and Rodriguez by Fisher's exact test).
Discussion
Incidence
To the best of our knowledge, we reported the largest series of BSI in heart transplant recipients [5] . We found an incidence of BSI of 24% with a 30-day mortality rate of 30%. The high incidence of BSI in our study was attributed to a high rate of late-onset BSI. In previous studies [1, 11, 12] , BSI is an early, nosocomial problem because it occurs mostly within the first 2 months after transplant. However, in our study, more than 50% of the BSI occurred after the first 6 months of transplant and the late-onset BSI was nosocomial in 65% of our cases.
Pathogen
Gram-negative bacteria have been described as the most frequent etiologic agents of BSI after liver transplantation [13] and kidney transplantation [14] . In heart transplantation, Gram-positive bacteria have been reported more frequently [1, 11] . However, in this study, we found a higher proportion of Gram-negative microorganisms, except during the months 2-6 when Gram-positives predominated. This trend toward a predominance of Gram-negative bacteria has recently been reported by Rodriguez et al. [5] . The incidence of nosocomial BSI due to the major Gram-negative bacteria increased over time. This trend of Gram-negative bacteria in nosocomial infection is similar to what has been reported previously at our hospital [7, 15] . Gram-negative bacteria accounted for more than 55% of nosocomially acquired microbial agents at our hospital. Pseudomanas aeruginosa, E. coli, E. cloaca, Klebsiela pneumoniae, and A. baumannii were the five most frequent Gram-negative bacteria causing nosocomial BSI. Among the Gram-negative bacteria, we had a high incidence of BSI caused by Enterobacter species and A. baumannii. Enterobacter species and A. baumannii have emerged as important causes of nosocomial infection in recent years. The most common portal of entry was the genitourinary tract and gastrointestinal tract, which are similar to most other Gram-negative bacteria. Origination from the gastrointestinal tract is difficult to ascertain and the source of infection often cannot be identified [16, 17] . This may explain why most of the source of infection in our cases often cannot be defined.
For fungal infection, cryptococcosis is the third most common invasive infection in solid organ transplant recipients after candidiasis and aspergillosis [18] . The incidence of cryptococcal meningitis was about 0.5% and was higher in heart recipients compared to other transplant populations. The cryptococcal meningitis-related mortality in transplant recipients was 50% and was frequently associated with altered mental status, absence of headache, and liver failure. Here, we have a similar result. Two patients had cryptococcal meningitis and one patient with altered consciousness died of severe sepsis.
Mortality
Sepsis is associated with a considerable risk of death, with the Sepsis Occurrence in Acutely ill Patients (SOAP) study [19] reporting mortality rates of 27% for patients with sepsis, increasing to 32% and 54% for patients with severe sepsis and septic shock, respectively. Here, our mortality rate of 30% is similar to what has been reported previously in nontransplant patients with nosocomial BSI at our hospital [9] . Heart transplantation itself will not increase the mortality in patients with BSI. However, patients with BSI were more likely to die if the infection was caused by Pseudomonal species, fungus, or Cryptococcus neoformans, or if there was a severe sepsis. The mortality was not related to nosocomial infection, polymicrobial infection, and time of onset.
Immunosuppression
The actual immunosuppression of the individual patients is listed in Table 3 . In our patients, we kept the maintenance immunosuppression in bacteremic patients without severe sepsis because the mortality rate in this group was 0%. There is no need to modify immunosuppressive therapy in patients with stable BSI. However, because of a mortality of 54% in those patients with severe sepsis, it is logical to decrease or stop immunosuppression levels and follow the cardiac function at a regular interval [20] .
In summary, there was a high incidence of BSI after heart transplantation in Taiwan, especially infections caused by Enterobacter species and A. baumannii. Mortality was high in patients with infection caused by Pseudomonas, Candida, and Cryptococcus, and in patients with severe sepsis. 
